Interestingly, patients with IGF-1 and tumour control that had impairment in QoL and symptoms according to paPASQ did not statistically differences in the time since diagnosis in comparison with patients with IGF-1 and tumour control that showed stable QoL and mild symptomatology (data not shown). The gene discussed is IGF1; the disease is neoplasm.